Bud Romine - The first patient taking Gleevec - Chronic Myeloid Leukemia
Bud Romine was the first patient in the world starting to take Gleevec in June 25, 1998
''For the first time, patients with a specific form of leukemia will receive an investigational drug therapy aimed precisely at the molecules causing their cancer. The first patient, 68-year-old Bud Romine from Tillamook, Ore., will take his first dose of the experimental drug on Thursday, June 25, 1998, at Oregon Health Sciences University.''
More Information at OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia
''For the first time, patients with a specific form of leukemia will receive an investigational drug therapy aimed precisely at the molecules causing their cancer. The first patient, 68-year-old Bud Romine from Tillamook, Ore., will take his first dose of the experimental drug on Thursday, June 25, 1998, at Oregon Health Sciences University.''
More Information at OHSU Scientists Begin Human Trials Of A Drug Aimed At The Underlying Cause Of Chronic Myelogenous Leukemia
VIDEOS
The first day of clinical trials for Gleevec, Bud and Yvonne from DNA LearningCenter
Getting the diagnosis of chronic myeloid leukemia, Bud from DNA LearningCenter
Bloodcount returns to normal with Gleevec, Bud and Yvonne from DNA LearningCenter
The first day of clinical trials for Gleevec, Bud and Yvonne from DNA LearningCenter
Getting the diagnosis of chronic myeloid leukemia, Bud from DNA LearningCenter
Bloodcount returns to normal with Gleevec, Bud and Yvonne from DNA LearningCenter
''Bud Romine was diagnosed with incurable cancer in 1994. He was given three years to live. In 1996 a newspaper article caught his eye.
The article described the work of a local doctor, Brian Druker, who was testing a new kind of cancer drug. In 1997, months away from death, Bud Romine became the first patient ever to take Gleevec''
